Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Unity Biotechnology raises $116mm through Series B round; $35mm extension added

Executive Summary

Unity Biotechnology Inc. raised $116mm through its Series B round from new investors Arch Venture Partners, Baillie Gifford, Fidelity Management & Research Co., Partner Fund Management, and Venrock, along with Bezos Expeditions and returning backers Wuxi PharmaTech and Mayo Clinic Ventures. Unity is developing therapies to selectively eliminate senescent cells from the body to treat diseases of aging. Series B proceeds will help expand R&D activities and advance the first preclinical candidates (for inflammatory joint diseases and ophthalmic conditions) into clinical trials.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies